Betamethasone Dipropionate; Calcipotriene Hydrate Patent Expiration
Betamethasone Dipropionate; Calcipotriene Hydrate is used for treating plaque psoriasis. It was first introduced by Leo Pharma As
Betamethasone Dipropionate; Calcipotriene Hydrate Patents
Given below is the list of patents protecting Betamethasone Dipropionate; Calcipotriene Hydrate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Taclonex | US6753013 | Pharmaceutical composition |
Jan 27, 2020
(Expired) | Leo Pharma As |
| Taclonex | US6787529 | Topical composition |
Jan 27, 2020
(Expired) | Leo Pharma As |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Betamethasone Dipropionate; Calcipotriene Hydrate's patents.
Latest Legal Activities on Betamethasone Dipropionate; Calcipotriene Hydrate's Patents
Given below is the list recent legal activities going on the following patents of Betamethasone Dipropionate; Calcipotriene Hydrate.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Post Issue Communication - Certificate of Correction | 08 Jun, 2007 | US6787529 |
| Recordation of Patent Grant Mailed Critical
| 07 Sep, 2004 | US6787529 |
| Patent Issue Date Used in PTA Calculation Critical
| 07 Sep, 2004 | US6787529 |
| Issue Notification Mailed Critical
| 19 Aug, 2004 | US6787529 |
| Receipt into Pubs | 11 Aug, 2004 | US6787529 |
| Dispatch to FDC | 09 Aug, 2004 | US6787529 |
| Workflow - Drawings Finished | 09 Aug, 2004 | US6787529 |
| Application Is Considered Ready for Issue Critical
| 09 Aug, 2004 | US6787529 |
| Receipt into Pubs | 21 Jul, 2004 | US6787529 |
| Issue Fee Payment Received Critical
| 20 Jul, 2004 | US6787529 |
Betamethasone Dipropionate; Calcipotriene Hydrate's Family Patents
